Ability to hit deadlines, not cost, top CRO quality, survey finds

By Antoine Durivaux

- Last updated on GMT

Related tags: Contract research organisation, Clinical trial, Contract research organization

19 out of 21 pharmaceutical companies surveyed by Cutting Edge Information ranked a contract research organisation’s ability to hit trial deadlines as either “extremely important” or very “important,” making it the top quality identified by respondents.

Jeremy Spivey, research analyst at Cutting Edge and author of the report, told Outsourcing-Pharma that he had noticed a large number of cancellations and deferments in recent weeks, but that drugmakers were not reporting a net fall in contract research organisation (CRO) deals.

CROs bring things to the table in terms of breadth of experience and the personnel management of clinical trials​,” he said.

The report, titled: “Clinical Outsourcing Strategy: Selecting Partners and Managing Relationships” finds that failing to meet clinical trial deadlines is often unavoidable at some stage in the drug development process.

However, “having the ability to gauge how trial protocols will manifest in real life enables CROs to help sponsors plan better trials and budget based on real-world projections,” ​Spivey writes.

It is this capacity that the new report’s author argues, will tend to count more to a sponsor than tendering the lowest bid.

Spivey also gave Outsourcing-Pharma details of the survey’s participants:

-Six were large, global pharmaceutical or biotech companies with multiple approved products and earnings of over $10bn dollars;

-Five were medium-size companies with at least one approved product and earnings of over $1bn;

-Five participants were small pharmaceutical companies without an approved product on the market;

Additionally we spoke with two consultants,”​ Spivey said. “One was an expert in patient recruitment and had assisted multiple top pharmaceutical companies in designing protocols to maximize recruitment.

Another specialised in helping smaller pharmaceutical companies manage their contracting and relationships with CROs. Each of our interviewees had experience working with large, multinational CROs as well as niche providers.”

Related news

Show more

Related products

show more

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Covance Touchless Drug and Device Vigilance Vision

Covance Touchless Drug and Device Vigilance Vision

Covance Patient Safety | 01-Sep-2020 | Data Sheet

Automation tools enable organizations to identify patterns in structured and unstructured data and facilitate automation of the entire product vigilance...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Related suppliers

Follow us


View more